Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
TVGNW
TVGNW
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
TVGNW News
TEVOGEN BIO HOLDINGS INC - AGREEMENT MAY TRANSFORM TEVOGEN INTO A PROFITABLE HEALTHCARE BUSINESS
Feb 26 2026
moomoo
TEVOGEN ENTERS LETTER OF INTENT TO ASSESS POSSIBLE ACQUISITION OF SCIOMETRIX AND ITS DIGITAL CARE MANAGEMENT PLATFORM, CLINICUS
Feb 26 2026
moomoo
TEVOGEN BOARD CONSIDERS POSSIBLE ONE-TIME SPECIAL CASH DIVIDEND FOR SHAREHOLDERS
Jan 30 2026
moomoo
Tevogen Addresses Financial Report, Emphasizing Robust Capital Efficiency and Minimal Cash Burn
Nov 03 2025
Newsfilter
Tevogen Executives Connect with Business and Community Leaders to Showcase Recent Achievements
Oct 29 2025
Newsfilter
Tevogen Provides Update on TVGN 489 Amid Increasing Interest from Long COVID Patients
Oct 15 2025
Newsfilter
Tevogen Achieves Significant Progress in AI Efforts to Improve T Cell–Based Therapies with 100x Expansion of PredicTcell™ Beta Data
Sep 25 2025
Newsfilter
Tevogen Praises HHS for Tackling Long COVID, Highlights TVGN 489's Potential Benefits for 20 Million Americans
Sep 19 2025
Newsfilter
Tevogen's CIO and Head of Tevogen.AI, Mittul Mehta, to Participate in Startup Forum Panel at Databricks DATA + AI World Tour in Boston
Sep 10 2025
Newsfilter
Tevogen Projects Approximately $6.5 Billion in Revenue Over 5 Years for Liver Cancer Prevention Product Targeting High-Risk Chronic Hepatitis B Patients
Sep 09 2025
Newsfilter
Tevogen Reveals Valuation of Essential Assets and Future Projections for Pipeline Products Targeting EBV-Related Leukemia and Lymphomas
Sep 04 2025
Newsfilter
Tevogen Highlights the Significance of Targeted Immunotherapies, Such as TVGN 489, for At-Risk Individuals Infected with SARS-CoV-2
Sep 03 2025
Newsfilter
Tevogen Thanks Yale for Acknowledging Dr. Ryan Saadi and the Company's Commitment to Health Equity
Aug 26 2025
Newsfilter
Tevogen Reports Ongoing Growth in Institutional Ownership for Q2 2025; 72% of Investors Either Increased or Sustained Their Holdings
Aug 25 2025
Newsfilter
Tevogen Honored in BINJE's BEST Health Care 2025 for Promoting Health Equity and Sustainable Biopharmaceuticals
Aug 22 2025
Newsfilter
Tevogen Bio Secures Up to $50 Million in Financing to Support R&D and Clinical Development Initiatives
Aug 19 2025
Newsfilter
Show More News
